Cargando…

Optimizing PSMA Radioligand Therapy for Patients with Metastatic Castration-Resistant Prostate Cancer. A Systematic Review and Meta-Analysis

The aim of the review was to evaluate patient and treatment characteristics for patients with metastatic castration-resistant prostate cancer (mCRPC) treated with PSMA radioligand therapy (PRLT) associated with above-average outcome. The systematic review and meta-analysis followed recommendations b...

Descripción completa

Detalles Bibliográficos
Autores principales:	von Eyben, Finn Edler, Bauman, Glenn, von Eyben, Rie, Rahbar, Kambiz, Soydal, Cigdem, Haug, Alexander R., Virgolini, Irene, Kulkarni, Harshad, Baum, Richard, Paganelli, Giovanni
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2020
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7730994/ https://www.ncbi.nlm.nih.gov/pubmed/33260535 http://dx.doi.org/10.3390/ijms21239054

Ejemplares similares

Metastatic extent predicts survival as patients with metastatic castration-resistant prostate cancer are treated with (177)Lu-PSMA radioligand therapy
por: von Eyben, Finn Edler, et al.
Publicado: (2020)

(177)Lu-PSMA radioligand therapy of predominant lymph node metastatic prostate cancer
por: von Eyben, Finn Edler, et al.
Publicado: (2019)

(68)Ga-PSMA PET/CT for Patients with PSA Relapse after Radical Prostatectomy or External Beam Radiotherapy
por: von Eyben, Finn Edler, et al.
Publicado: (2021)

Third-line treatment and (177)Lu-PSMA radioligand therapy of metastatic castration-resistant prostate cancer: a systematic review
por: von Eyben, Finn Edler, et al.
Publicado: (2017)

On the Way for Patients with Prostate Cancer to the Best Use of PSMA
por: von Eyben, Finn Edler, et al.
Publicado: (2022)

Pretest PSA and Restaging PSMA PET/CT Predict Survival in Biochemically Recurrent Prostate Cancer
por: von Eyben, Rie, et al.
Publicado: (2023)

(177)Lu-PSMA Radioligand Therapy Is Favorable as Third-Line Treatment of Patients with Metastatic Castration-Resistant Prostate Cancer. A Systematic Review and Network Meta-Analysis of Randomized Controlled Trials
por: von Eyben, Finn E., et al.
Publicado: (2021)

(177)Lu-PSMA-617 radioligand therapy for a patient with lymph node metastatic prostate cancer
por: von Eyben, Finn E., et al.
Publicado: (2017)

A Risk Model for Patients with PSA-Only Recurrence (Biochemical Recurrence) Based on PSA and PSMA PET/CT: An Individual Patient Data Meta-Analysis
por: von Eyben, Rie, et al.
Publicado: (2022)

PSMA diagnostics and treatments of prostate cancer become mature
por: von Eyben, Finn Edler, et al.
Publicado: (2018)

Correction: von Eyben et al. A Risk Model for Patients with PSA-Only Recurrence (Biochemical Recurrence) Based on PSA and PSMA PET/CT: An Individual Patient Data Meta-Analysis. Cancers 2022, 14, 5461
por: von Eyben, Rie, et al.
Publicado: (2023)

Separate Chinese lines for prostate cancer?
por: von Eyben, Finn Edler
Publicado: (2019)

Molecular analysis of circulating tumor cells of metastatic castration-resistant Prostate Cancer Patients receiving (177)Lu-PSMA-617 Radioligand Therapy
por: Kessel, Katharina, et al.
Publicado: (2020)

Meta-Analysis of Gene Expressions in Testicular Germ Cell Tumor Histologies
por: von Eyben, Finn Edler, et al.
Publicado: (2020)

Comparison of [(18)F]PSMA-1007 with [(68)Ga]Ga-PSMA-11 PET/CT in Restaging of Prostate Cancer Patients with PSA Relapse
por: Hoffmann, Manuela A., et al.
Publicado: (2022)

Primary Staging of Prostate Cancer Patients with [(18)F]PSMA-1007 PET/CT Compared with [(68)Ga]Ga-PSMA-11 PET/CT
por: Hoffmann, Manuela A., et al.
Publicado: (2022)

Early side effects and first results of radioligand therapy with (177)Lu-DKFZ-617 PSMA of castrate-resistant metastatic prostate cancer: a two-centre study
por: Ahmadzadehfar, Hojjat, et al.
Publicado: (2015)

Response assessment using (68)Ga-PSMA ligand PET in patients undergoing (177)Lu-PSMA radioligand therapy for metastatic castration-resistant prostate cancer
por: Grubmüller, Bernhard, et al.
Publicado: (2018)

Testicular germ cell tumors type 2 have high RNA expression of LDHB, the gene for lactate dehydrogenase subunit B
por: von Eyben, Finn Edler, et al.
Publicado: (2021)

Analysis of PSMA expression and outcome in patients with advanced Prostate Cancer receiving (177)Lu-PSMA-617 Radioligand Therapy
por: Seifert, Robert, et al.
Publicado: (2020)

Salivary Gland Toxicity of PSMA-Targeted Radioligand Therapy with (177)Lu-PSMA and Combined (225)Ac- and (177)Lu-Labeled PSMA Ligands (TANDEM-PRLT) in Advanced Prostate Cancer: A Single-Center Systematic Investigation
por: Langbein, Thomas, et al.
Publicado: (2022)

Prior therapies as prognostic factors of overall survival in metastatic castration-resistant prostate cancer patients treated with [(177)Lu]Lu-PSMA-617. A WARMTH multicenter study (the 617 trial)
por: Ahmadzadehfar, Hojjat, et al.
Publicado: (2020)

Hematologic safety of (177)Lu-PSMA-617 radioligand therapy in patients with metastatic castration-resistant prostate cancer
por: Groener, Daniel, et al.
Publicado: (2021)

Joint EANM/SNMMI procedure guideline for the use of (177)Lu-labeled PSMA-targeted radioligand-therapy ((177)Lu-PSMA-RLT)
por: Kratochwil, Clemens, et al.
Publicado: (2023)

PSMA Expression Predicts Early Biochemical Response in Patients with Metastatic Castration-Resistant Prostate Cancer under (177)Lu-PSMA-617 Radioligand Therapy
por: Widjaja, Liam, et al.
Publicado: (2021)

Determinants of outcome following PSMA-based radioligand therapy and mechanisms of resistance in patients with metastatic castration-resistant prostate cancer
por: Kostos, Louise, et al.
Publicado: (2023)

Response to [(177)Lu]Lu-PSMA radioligand therapy in metastatic castration-resistant prostate cancer patients presenting with only lymph node metastases
por: Zisser, Lucia, et al.
Publicado: (2022)

Metal-Based PSMA Radioligands
por: Gourni, Eleni, et al.
Publicado: (2017)

(177)Lu‐PSMA radioligand therapy effectiveness in metastatic castration‐resistant prostate cancer: An updated systematic review and meta‐analysis
por: Sadaghiani, Mohammad S., et al.
Publicado: (2022)

Intermittent Radioligand Therapy with (177)Lu-PSMA-617 for Oligometastatic Castration-Resistant Prostate Cancer
por: Mader, Nicolai, et al.
Publicado: (2023)

Radioligand therapy using [(177)Lu]Lu-PSMA-617 in mCRPC: a pre-VISION single-center analysis
por: Seifert, Robert, et al.
Publicado: (2020)

Predictors of overall survival in metastatic castration-resistant prostate cancer patients receiving [(177)Lu]Lu-PSMA-617 radioligand therapy
por: Ahmadzadehfar, Hojjat, et al.
Publicado: (2017)

Therapeutic response and side effects of repeated radioligand therapy with (177)Lu-PSMA-DKFZ-617 of castrate-resistant metastatic prostate cancer
por: Ahmadzadehfar, Hojjat, et al.
Publicado: (2016)

Outcome of (177)Lu-PSMA-617 Radioligand Therapy in Chemo-Refractory Patients with Metastatic Castration-Resistant Early-Onset Prostate Cancer
por: Mader, Nicolai, et al.
Publicado: (2021)

Salvage Radioligand Therapy with Repeated Cycles of (177)Lu-PSMA-617 in Metastatic Castration-Resistant Prostate Cancer with Diffuse Bone Marrow Involvement
por: Groener, Daniel, et al.
Publicado: (2021)

(177)Lu-PSMA-I&T Radioligand Therapy for Treating Metastatic Castration-Resistant Prostate Cancer: A Single-Centre Study in East Asians
por: Bu, Ting, et al.
Publicado: (2022)

Long-term outcome of (177)Lu-PSMA-617 radioligand therapy in heavily pre-treated metastatic castration-resistant prostate cancer patients
por: Yadav, Madhav Prasad, et al.
Publicado: (2021)

Radioligand therapy of metastatic castration-resistant prostate cancer: current approaches
por: Awang, Zool Hilmi, et al.
Publicado: (2018)

Pharmacological Optimization of PSMA-Based Radioligand Therapy
por: van der Gaag, Suzanne, et al.
Publicado: (2022)

Adoption of Lutetium-(177) PSMA radioligand therapy for metastatic castration resistant prostate cancer: a total population analysis in Germany from 2016 to 2020
por: Flegar, Luka, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_hflfflran25cuilb238db5vtio